Advanced Oncotherapy add “expert clinical knowledge” to the management team

Commenting on the appointment, Michael Sinclair, Executive Chairman of Advanced Oncotherapy LON:AVO said: “Dr Plowman has been a welcome source of expert clinical knowledge through his input to our advisory board and we look forward to extending his contribution to the Company in this new role. Few people in the UK can boast a higher level of expertise in radiation oncology or enthusiasm for supporting and pioneering new radiation technology than Nick and we are delighted to bring these to bear through his position on our Board.”

Also commenting, Dr Nick Plowman said: “It is great news for UK patients that London will spearhead this important advance in proton therapy. It is our mission to make this cutting-edge treatment more readily available to all those who need it and Advanced Oncotherapy are at the forefront with our technology. The next generation ‘LIGHT’ protons look to supplant current generation technology in many ways and we look forward to what we hope will be a great commercial success story with these machines.”

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk about the appointment of Dr Nick Plowman, Senior Clinical Oncologist at St Bartholomew’s Hospital (“Barts”) and the Hospital for Sick Children at Great Ormond Street (“GOSH”) in London, as a Non-Executive Director with immediate effect.

Dr Nick Plowman is the UK’s senior radiotherapist. Qualified through Cambridge (double first: medical sciences and natural sciences), Dr Plowman was appointed as consultant to St Bartholomew’s Hospital and GOSH, London in 1982. He is currently senior physician to both these hospitals. During these 35 years Dr Plowman has pioneered most of the new technologies in the field of Clinical Radiotherapy. He has the longest and widest experience in radiosurgery (Gamma Knife and Cyberknife) of the brain, followed by spine, and then radiosurgery of the body, and is the Medical Director of the Cyberknife Centre, London. St Bartholomew’s Hospital is the only UK centre with both these radiosurgical facilities in the UK.

Early in his career, and with his team at Barts, Dr Plowman introduced lens sparing ocular radiotherapy, the most precise radiation therapy method of its era, the blueprints for which were requested by and given to hospitals in Stanford, California, and Tokyo. This innovative process continued to be used at Barts, for the Moorfield’s ocular tumour practice, up until recently.

Dr Plowman’s team were the first in the UK to publish research on Tomotherapy/IMRT when this new technology became available in the UK at the Cromwell Hospital. He has published widely with over 350 research publications and edited textbooks including one on the complications of cancer management.

Dr Plowman developed an eager early interest in new proton beam technology, as the advantages for this therapy in clinical practice are significant. Dr Plowman became Chairman of the AVO Medical Advisory Board in October 2013 and has gradually acquired a significant personal holding in the company as detailed below.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked